TY - JOUR
T1 - Comparison of cystatin C- and creatinine-based estimated glomerular filtration rates for predicting all-cause mortality in Japanese patients with type 2 diabetes
T2 - the Fukuoka Diabetes Registry
AU - Ide, Hitoshi
AU - Iwase, Masanori
AU - Fujii, Hiroki
AU - Ohkuma, Toshiaki
AU - Kaizu, Shinako
AU - Jodai, Tamaki
AU - Kikuchi, Yohei
AU - Idewaki, Yasuhiro
AU - Sumi, Akiko
AU - Nakamura, Udai
AU - Kitazono, Takanari
N1 - Funding Information:
This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (Grant nos. 23249037, 23659353) for Masanori Iwase from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Publisher Copyright:
© 2016, Japanese Society of Nephrology.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background: There is little information about the predictive ability of cystatin C-based estimated glomerular filtration rates (eGFRCys) for all-cause mortality in Asian populations. We compared the discriminatory ability of eGFRCys for all-cause mortality with that of creatinine-based estimated glomerular filtration rates (eGFRCr) in Japanese patients with type 2 diabetes. Methods: A total of 4869 participants were classified into four categories (eGFR ≤29, 30–59, 60–89, and ≥90 ml/min/1.73 m2) by eGFRCr and eGFRCys, and followed up for a median of 3.3 years. Results: 150 deaths were identified. The multivariable-adjusted risk of all-cause mortality was significantly increased in eGFRCr ≤29 ml/min/1.73 m2 compared with eGFRCr ≥90 ml/min/1.73 m2 [hazard ratio (HR) 2.4 (95 % confidence interval (95 % CI) 1.2–5.0)], whereas it was significantly increased in eGFRCys 59 ml/min/1.73 m2 or lower [30–59 ml/min/1.73 m2, HR 1.9 (95 % CI 1.1–3.5); ≤29 ml/min/1.73 m2, HR 5.8 (95 % CI 2.8–12.0)]. Comparing eGFRCys with eGFRCr, the proportions of participants reclassified to lower and higher eGFR stages were 6.3 and 28.8 %, respectively. The multivariable-adjusted HRs for all-cause mortality were 1.8 (95 % CI 1.1–2.9) and 0.7 (95 % CI 0.4–1.1), respectively. The C statistic of the model including eGFRCys and other risk factors was significantly increased compared with the model including eGFRCr. The net reclassification improvement and the integrated discrimination improvement were significantly positive. Conclusions: Our findings suggest that eGFRCys has a stronger association with all-cause mortality and is superior to eGFRCr for predicting all-cause mortality in Japanese patients with type 2 diabetes.
AB - Background: There is little information about the predictive ability of cystatin C-based estimated glomerular filtration rates (eGFRCys) for all-cause mortality in Asian populations. We compared the discriminatory ability of eGFRCys for all-cause mortality with that of creatinine-based estimated glomerular filtration rates (eGFRCr) in Japanese patients with type 2 diabetes. Methods: A total of 4869 participants were classified into four categories (eGFR ≤29, 30–59, 60–89, and ≥90 ml/min/1.73 m2) by eGFRCr and eGFRCys, and followed up for a median of 3.3 years. Results: 150 deaths were identified. The multivariable-adjusted risk of all-cause mortality was significantly increased in eGFRCr ≤29 ml/min/1.73 m2 compared with eGFRCr ≥90 ml/min/1.73 m2 [hazard ratio (HR) 2.4 (95 % confidence interval (95 % CI) 1.2–5.0)], whereas it was significantly increased in eGFRCys 59 ml/min/1.73 m2 or lower [30–59 ml/min/1.73 m2, HR 1.9 (95 % CI 1.1–3.5); ≤29 ml/min/1.73 m2, HR 5.8 (95 % CI 2.8–12.0)]. Comparing eGFRCys with eGFRCr, the proportions of participants reclassified to lower and higher eGFR stages were 6.3 and 28.8 %, respectively. The multivariable-adjusted HRs for all-cause mortality were 1.8 (95 % CI 1.1–2.9) and 0.7 (95 % CI 0.4–1.1), respectively. The C statistic of the model including eGFRCys and other risk factors was significantly increased compared with the model including eGFRCr. The net reclassification improvement and the integrated discrimination improvement were significantly positive. Conclusions: Our findings suggest that eGFRCys has a stronger association with all-cause mortality and is superior to eGFRCr for predicting all-cause mortality in Japanese patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=84976293845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976293845&partnerID=8YFLogxK
U2 - 10.1007/s10157-016-1296-2
DO - 10.1007/s10157-016-1296-2
M3 - Article
C2 - 27339449
AN - SCOPUS:84976293845
SN - 1342-1751
VL - 21
SP - 383
EP - 390
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 3
ER -